- 38% of patients regrew most of their hair in 6 months
- Adults with severe, long-term hair loss could benefit
- Not yet available—still under FDA review
This new treatment could help many people with severe hair loss finally see real regrowth.
Imagine looking in the mirror after years of avoiding it. You see hair—real, noticeable hair—growing back on your scalp. For people with severe alopecia areata, that moment felt impossible. Now, a new study shows it may be within reach.
Alopecia areata affects about 6.8 million people in the U.S. It’s not just stress or aging. It’s an autoimmune disease. That means the body’s immune system mistakenly attacks hair follicles. The result? Sudden, patchy hair loss. Sometimes, people lose all scalp or body hair. There’s no cure. Current treatments often don’t work well—or stop working over time.
Many rely on steroid shots or creams. But these can sting, cause skin thinning, or only help mild cases. Some take older JAK inhibitors—drugs that change immune signals. But they’re not approved for alopecia and may have serious side effects.
The game has changed
For years, scientists thought reversing severe hair loss was unlikely. They believed follicles were too damaged. But recent research flipped that idea. Follicles aren’t dead. They’re just “asleep.” The immune attack silences them. Stop the attack, and hair can grow again.
Here’s the twist: this new drug wakes them up—safely and effectively.
Deuruxolitinib is a pill that blocks two key proteins: JAK1 and JAK2. Think of these like broken switches in the immune system. When they’re stuck “on,” the body keeps attacking hair. This drug flips them “off.” It’s like removing a jammed alarm so the body can reset.
It’s selective—meaning it targets only the troublemakers. That may lower the risk of side effects.
The study included 515 adults with severe alopecia. All had lost at least half their hair for six months or more. They were split into three groups. One got a placebo. The others took deuruxolitinib—either 8 mg or 12 mg—twice daily for 24 weeks (about 6 months).
No one knew who got what. Doctors checked hair regrowth using the SALT score. That’s a tool that measures how much scalp is covered. A score under 20 means 80% or more hair is back—close to full regrowth.
Results that speak for themselves
After 6 months, only 1 in 125 people on placebo hit that target. But 1 in 3 on the 8 mg dose did. On the 12 mg dose? Nearly 2 in 5—38.3%—regrew most of their hair.
That’s not just statistically significant. It’s life-changing.
One in three people on the lower dose also saw major improvement in eyebrow and eyelash regrowth. Many reported feeling more confident, less anxious.
Most side effects were mild—like headaches or cold symptoms. A few had higher cholesterol or mild infections. No major safety red flags came up. The drug was well tolerated overall.
But there’s a catch.
This doesn’t mean this treatment is available yet.
Experts say the results are promising—but not final. Dr. Emma Reynolds, a dermatologist not involved in the study, said: “We’re finally seeing targeted therapies that work for alopecia. This drug fits that trend. But long-term use? We don’t know if hair stays or falls out again.”
She adds: “For patients who’ve tried everything, this could be a real option. But we need to watch for rare side effects over time.”
So what does this mean for you?
If you or a loved one has severe alopecia, talk to your dermatologist. This drug isn’t on the market yet. It’s under FDA review. That process can take months. Even if approved, it may not be right for everyone.
It’s not a cure. And it’s not for mild cases. You’ll likely need to keep taking it. Stop the drug, and hair loss may return.
Still, for many, this is hope in pill form.
The study only lasted 6 months. That’s not long enough to know if results last. Also, the group was limited—adults 18–65 with chronic, severe hair loss. It didn’t include kids, pregnant women, or those with other autoimmune diseases.
The trial was well-run. But real-world use is different. Some people may respond better than others. Genetics, lifestyle, and other health issues could affect results.
What’s next?
The drug maker is running longer studies. They’re tracking patients for up to two years. They want to know: does hair keep growing? Are there late side effects? Can people take breaks?
FDA approval could come in late 2026. If it happens, deuruxolitinib would be one of the first oral treatments approved just for alopecia areata.
Until then, researchers urge patience. Science moves carefully—for good reason. Every step ensures safety, not just speed.
